BTIG keeps USD 110.00 target for Edwards Lifesciences stock

Published on 10/20/2026 at 19:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results come next on November 4, 2026. Edwards Lifesciences stock stood at EUR 78.37 at Lang & Schwarz on October 20, 2026 at 7:37 p.m. CEST.

Analyst target and reporting date

BTIG kept a USD 110.00 target for Edwards Lifesciences on October 9, 2026.
Second-quarter revenue reached USD 1.74 billion, while net income was USD 241.9 million.
Edwards Lifesciences stock stood at EUR 78.37 at Lang & Schwarz on October 20, 2026 at 7:37 p.m. CEST.
The company plans to report third-quarter results on November 4, 2026.

Isometrische 3D-Darstellung der Medizintechnik-Wertschöpfungskette: Labor, Fertigung, Krankenhaus — Edwards Lifesciences US28176E1082 isometrische 3D-Illustration der Medizintechnik-Wertschöpfungskette von Labor über Fertigung zu Krankenhaus, Illustration mit AI erstellt.

On October 9, 2026, BTIG reiterated a Buy rating for Edwards Lifesciences and kept its price target at USD 110.00, according to Markets Insider. Against the USD 87.98 NYSE price at 1:41 p.m. ET on October 20, 2026, the target stands 25.01 percent above the stock. Edwards Lifesciences was at EUR 78.37 at Lang & Schwarz on October 20, 2026 at 7:37 p.m. CEST.

Revenue grew in the second quarter

Edwards Lifesciences generated USD 1.74 billion in revenue in the second quarter of 2026, up 13.6 percent from the same quarter of 2025. Net income attributable to common shareholders was USD 241.9 million, while adjusted earnings per share reached USD 0.78 against consensus of USD 0.74, according to MarketBeat. The revenue comparison adds operating context to the analyst target, while the earnings comparison shows a USD 0.04 beat.

Stock remains below its yearly high

On the NYSE, Edwards Lifesciences last traded at USD 87.98 on October 20, 2026 at 1:41 p.m. ET. Its USD 74.66 to USD 96.29 52-week range places the price 8.63 percent below the high and 17.84 percent above the low. Trading volume was 628,211 shares at that timestamp. The company had a market capitalization of USD 50.7 billion.

Valuation meets the next report date

The stock carried a trailing P/E ratio of 50.57 on October 20, 2026. Edwards Lifesciences plans to announce results for the quarter ended September 30, 2026, after the market closes on November 4, 2026, with its conference call scheduled for 5:00 p.m. ET, according to Edwards Lifesciences. That date gives the USD 110.00 target its next scheduled company test.

Comparison with peers

Edwards Lifesciences: P/E 50.57, market capitalization USD 50.7 billion as of October 20, 2026.
Abbott Laboratories (NYSE, USD): P/E 33.09, market capitalization USD 178.2 billion as of October 20, 2026.
Medtronic (NYSE, USD): P/E 23.30, market capitalization USD 121.0 billion as of October 20, 2026.

What the target means for the stock

BTIG's USD 110.00 target sits above the current NYSE quote, but the valuation gap to Abbott Laboratories and Medtronic remains visible in the P/E figures. The next earnings release on November 4, 2026, will provide the next quantified test of the company's second-quarter growth rate and full-year execution.